Medical treatment of obesity: The past, the present and the future

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 4, 2014, Pages 665-684

  Bray, George A ^a  

^a NONE   (United States)

Author keywords

Combination therapy; Glucagon like peptide 1 agonists; Orlistat; Serotonergic drugs; Sympathomimetic drugs

Indexed keywords

2,4 DINITROPHENOL; AMFEBUTAMONE; AMINOREX; AMPHETAMINE; ANTIOBESITY AGENT; CAFFEINE; CHOLECYSTOKININ; DAPICLERMIN; DEXFENFLURAMINE; DOPAMINE; ECOPIPAM; EPHEDRA SINICA EXTRACT; EPHEDRINE; FENFLURAMINE; LEPTIN; LORCASERIN; NEUROPEPTIDE Y; OXYNTOMODULIN; PEPTIDE YY; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; THYROID HORMONE; TOPIRAMATE; UNINDEXED DRUG; ZONISAMIDE; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; FRUCTOSE; LACTONE;

ANTIQUITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HISTORY; HUMAN; LIVER INJURY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYXEDEMA; NONHUMAN; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW (TOPIC); WAR; DRUG COMBINATION; GLUCAGON-LIKE PEPTIDE-1 AGONISTS; REVIEW; SEROTONERGIC DRUGS; SYMPATHOMIMETIC DRUGS; THERAPY; WEIGHT REDUCTION;

COMBINATION THERAPY; GLUCAGON-LIKE PEPTIDE-1 AGONISTS; ORLISTAT; SEROTONERGIC DRUGS; SYMPATHOMIMETIC DRUGS;

ANTI-OBESITY AGENTS; BENZAZEPINES; DRUG THERAPY, COMBINATION; FRUCTOSE; HUMANS; LACTONES; OBESITY; PHENTERMINE; WEIGHT LOSS;

EID: 84910003856     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.07.015     Document Type: Review

References (76)

1. Olser W. Recent advances in medicine. Science 1891 Mar 27;17(425):170-1. PubMed PMID: 17817030. [Epub 1891/03/27. eng].
2. Bray GA. The battle of the bulge; a history of obesity research. Pittsburgh: Dorrance Publishing; 2007.
3. Flemyng MN. A discourse on the nature, causes, and cure of corpulency. Illustrated by a remarkable case, read before the Royal Society, November 1757. London: Malcolm Flemyng; 1760.
4. Short T. A discourse concerning the causes and effects of corpulency together with the method for its prevention and cure. London: J. Roberts; 1727.
5. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity Silver Spring 2011 Jan;19(1): 110-20. PubMed PMID: 20559296. [Epub 2010/06/19. eng].
6. Bonet T. A guide to the practical physician: Shewing, from the most approved authors, both ancient and modern, the truest and safest way of curing all diseases, internal and external, whether by medicine, surgery or diet. In: Flesher T, editor; 1684. London.
7. Gull. On a cretinoid state supervening in adult life in women. Trans Clin Soc Lond 1873;74(7):180-5.
8. Putnam. Cases of myxoedema and acromegalia treated with benefit by sheep0s thyroids: recent observations respecting the pathology of the cachexias following disease of the thyroid; clinical relationships of Grave0s disease and acromegalia. Am J Med Sci 1893;106:125-48.
9. Bray G. Thyroid hormones in the treatment of obesity. In: Bray GA, editor. Obesity in perspective. Fogarty International Center series of preventive med, vol. 2. Washington, D.C: U.S. Govt Prtg Office; 1976. p. 449-56. Section IV, Part, [chapter 55]. (DHEW Publication #75-708).
10. Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol 2007 Jul; 48(2):115-7. PubMed PMID: 17475379. [Epub 2007/05/04. eng].
11. Nathanson MH. The central action of betaaminopropylbenzene (benzedrine): clinical observations. J Am Med Assoc 1937; 108(7):528-31.
12. Lesses MF, Myerson A. Human autonomic pharmacology. N Engl J Med 1938;218(3):119-24.
13. Kalant OJ. The amphetamines, toxicity and addiction, vol. xii. Springfield, Ill: Thomas; 1966. p. 151.
14. Leibowitz SF, Rossakis C. Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol. Eur J Pharmacol 1978 Dec 15;53(1):69-81. PubMed PMID: 738361. [Epub 1978/12/ 15. eng].
15. Heil G, Ross S. Chemical agents affecting appetite. In: Bray GA, editor. Obesity in perspective. Fogarty International Center series on preventive med; 1976. p. 409-18.
16. Burland W. A review of experience with fenfluramine. In: Bray GA, editor. Obesity in perspective. Fogarty International Center Series on Preventive Med, vol. 2; 1976. p. 429-40.
17. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989 Nov 11;2(8672):1142-5. PubMed PMID: 2572857. [Epub 1989/11/11. eng].
18. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992 Apr;16(4):269-77. PubMed PMID: 1318281.
19. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992 May;51(5):581-5. PubMed PMID: 1445528.
20. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997 Aug 28;337(9):581-8. PubMed PMID: 9271479.
21. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 Dec 1;372(6505):425-32. PubMed PMID: 7984236. [Epub 1994/12/01. eng].
22. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J Am Med Assoc 1999 Oct 27;282(16):1568-75. PubMed PMID: 10546697. [Epub 1999/11/05. eng].
23. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006 Oct;4(4):275-82. PubMed PMID: 17011500. [Epub 2006/10/03]. eng.
24. Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity Silver Spring 2007 Jul;15(7):1717-31. PubMed PMID: 17636090. [Epub 2007/07/20. eng].
25. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000 Dec 23-30;356(9248):2119-25. PubMed PMID: 11191537. [Epub 2001/02/24. eng].
26. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010 Sep 2;363(10):905-17. PubMed PMID: 20818901. [Epub 2010/09/08. eng].
27. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008 Nov 29;372(9653):1906-13. PubMed PMID: 18950853. [Epub 2008/10/28. eng].
28. Goldstein DJ, Rampey Jr AH, Roback PJ, Wilson MG, Hamilton SH, Sayler ME, et al. Efficacy and safety of long-term fluoxetine treatment of obesityemaximizing success. Obes Res 1995 Nov;3(Suppl. 4):481S-90S. PubMed PMID: 8697047. [Epub 1995/11/01. eng].
29. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002 Jul;10(7):633-41. PubMed PMID: 12105285.
30. Gadde KM, Kopping MF, Wagner 2nd HR, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012 Nov 12;172(20):1557-64. PubMed PMID: 23147455. Pubmed Central PMCID: 3753218. [Epub 2012/11/14. eng].
31. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006 Feb;27(1):73-100. PubMed PMID: 16306385. [Epub 2005/11/25. eng].
32. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 Nov 17;353(20):2121-34. PubMed PMID: 16291982. [Epub 2005/11/18. eng].
33. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006 Feb 15;295(7):761-75. PubMed PMID: 16478899. [Epub 2006/02/16. eng].
34. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. J Am Med Assoc 2008 Apr 2;299(13):1547-60. PubMed PMID: 18387931. [Epub 2008/04/05. eng].
35. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. J Am Med Assoc 2003 Apr 9; 289(14):1826-32. PubMed PMID: 12684362. [Epub 2003/04/10. eng].
36. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981 Feb;34(2):154-60. PubMed PMID: 6259918. [Epub 1981/02/01. eng].
37. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003 Sep 4;349(10):941-8. PubMed PMID: 12954742. [Epub 2003/09/05. eng].
38. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005 Aug;54(8):2390-5. PubMed PMID: 16046306. [Epub 2005/07/28. eng].
39. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011 Oct 4;155(7): 434-47. PubMed PMID: 21969342. [Epub 2011/10/05. eng].
40. Torgerson J, Hauptman J, Boldrin M, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients; 2004. p. 155-61.
41. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. J Am Med Assoc 2005 Jun 15;293(23):2873-83. PubMed PMID: 15956632. [Epub 2005/06/16. eng].
42. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated metaanalysis. BMJ 2007 Dec 8;335(7631):1194-9. PubMed PMID: 18006966. Pubmed Central PMCID: 2128668. [Epub 2007/ 11/17. eng].
43. Bray G, Greenway F. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59:151-84.
44. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ 2013:346. 2013-04-12 11:48:51.
45. Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from Orlistat Clinical Trials. Obes Facts 2012; 5(4):485-94.
46. Bray G. A guide to obesity and the metabolic syndrome. Boca Raton: CRC Press, Taylor and Francis Group; 2011.
47. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67(1):27-55. PubMed PMID: 17209663. [Epub 2007/01/11. eng].
48. FDA. Briefing information: meeting of the Endocrinologic and Metabolic Drugs Advisory Committee; May 10, 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrino logicandMetabolicDrugsAdvisoryCommittee/UCM303198.pdf.
49. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010 Jul 15;363(3):245-56. PubMed PMID: 20647200. [Epub 2010/07/ 22. eng].
50. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011 Oct;96(10):3067-77. PubMed PMID: 21795446. [Epub 2011/07/29. eng].
51. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity Silver Spring 2012 Jul;20(7): 1426-36. PubMed PMID: 22421927. [Epub 2012/03/17. eng].
52. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity Silver Spring 2012 Feb;20(2):330-42. PubMed PMID: 22051941. Pubmed Central PMCID: 3270297. [Epub 2011/11/05. eng].
53. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011 Apr 16;377(9774):1341-52. PubMed PMID: 21481449. [Epub 2011/04/13. eng].
54. FDA. Briefing information: meeting of the Endocrinologic and Metabolic Drugs Advisory Committee; February 22, 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrino logicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf.
55. Brownell K. The learn manual for weight management. Dallas: American Health Publishing Company.
56. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012 Oct 25;367(17):1577-9. PubMed PMID: 23050510. [Epub 2012/10/12. eng].
57. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012 Feb;95(2):297-308. PubMed PMID: 22158731. Pubmed Central PMCID: 3260065. [Epub 2011/12/14. eng].
58. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity Silver Spring 2009 Jan;17(1):30-9. PubMed PMID: 18997675. [Epub 2008/11/11. eng].
59. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010 Aug 21;376(9741):595-605. PubMed PMID: 20673995. [Epub 2010/08/03. eng].
60. ContraveDocument. Contrave (Naltrexone SR/bupropion SR combination) advisory committee briefing document. NDA 200063. Endocrinologic and Metabolic Drugs Advisory Committee meeting; December 7, 2010.
61. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity Silver Spring 2009 Sep;17(9):1730-5. PubMed PMID: 19300434. [Epub 2009/03/21. eng].
62. QNEXAdoc. VI-0521 (QNEXA®) Advisory committee briefing document. NDA 022580. Endocrinologic and Metabolic Drugs Advisory Committee meeting; July 15, 2010. p. 2010.
63. Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010 Oct;12(10):876-82. PubMed PMID: 20920040. [Epub 2010/10/06. eng].
64. Addy C, Jumes P, Rosko K, Li S, Li H, Maes A, et al. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. J Clin Pharmacol 2009 Oct; 49(10):1228-38. PubMed PMID: 19783715. [Epub 2009/09/29. eng].
65. Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006 Oct 31;47(5):614-25. PubMed PMID: 17066505. Pubmed Central PMCID: 2687747. [Epub 2006/10/27. eng].
66. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012 Apr 3;125(13):1695-703. PubMed PMID: 22474312. [Epub 2012/04/05. eng].
67. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007 Jul;100(7):395-404. PubMed PMID: 17566010. [Epub 2007/06/15. eng].
68. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012 Apr;35(4):731-7. PubMed PMID: 22442396. Pubmed Central PMCID: 3308305. [Epub 2012/03/ 24. eng].
69. Bushe CJ, Bradley AJ, Doshi S, Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract 2009 Dec;63(12):1743-61. PubMed PMID: 19840151. [Epub 2009/10/21. eng].
70. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity Silver Spring 2010 Sep;18(9):1739-46. PubMed PMID: 20094043. [Epub 2010/01/23. eng].
71. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001 Jul;281(1):E155-61. PubMed PMID: 11404233. [Epub 2001/06/19. eng].
72. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007 Jul 11;298(2):194-206. PubMed PMID: 17622601. [Epub 2007/07/12. eng].
73. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010 May;123(5):468.e9-468.e17. PubMed PMID: 20399326. [Epub 2010/04/20. eng].
74. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004 Sep-Oct;20(5):411-7. PubMed PMID: 15343588.
75. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009 Nov 7;374(9701):1606-16. PubMed PMID: 19853906. [Epub 2009/10/27. eng].
76. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, doseranging trial of topiramate for weight loss in obesity. Obes Res 2003 Jun;11(6):722-33. PubMed PMID: 12805393. [Epub 2003/06/14. eng].